Is Quantum Biopharma Ltd. (QNTM) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.1% / 30% | 53.5% / 30% | 28.3% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 6.1% / 33% | 53.5% / 33% | 28.3% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 4.8% / 33% | 42.0% / 33% | 22.2% / 33% | N/A | ✗ NOT HALAL |
| S&P | 6.1% / 33% | 53.5% / 33% | 28.3% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 4.8% / 33% | 42.0% / 33% | 22.2% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -346.9% | |
| Return on Assets (ROA) | -67.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$7M |
| Free Cash Flow | -$7M |
| Total Debt | $824,922 |
| Debt-to-Equity | 36.8 |
| Current Ratio | 1.1 |
| Total Assets | $17M |
Price & Trading
| Last Close | $3.83 |
| 50-Day MA | $4.03 |
| 200-Day MA | $12.66 |
| Avg Volume | 136K |
|
52-Week Range
$2.07
| |
About Quantum Biopharma Ltd. (QNTM)
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Quantum Biopharma Ltd. (QNTM) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Quantum Biopharma Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Quantum Biopharma Ltd.'s debt ratio?
Quantum Biopharma Ltd.'s debt ratio is 6.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 4.8%.
What are Quantum Biopharma Ltd.'s key financial metrics?
Quantum Biopharma Ltd. has a market capitalization of $20M. Return on equity stands at -346.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.